|Status : Published
|Published On : Dec, 2023
|Report Code : VRHC1043
|Industry : Healthcare
|Available Format :
|Page : 200
The Global Non-Invasive Prenatal Testing (NIPT) Market was valued at USD 2.8 billion in 2023 and is anticipated to reach USD 6.83 billion by 2030, witnessing a CAGR of 12.35% during 2025-2030. Non-invasive prenatal testing (NIPT) is a sensitive diagnostic method for identifying specific chromosomal abnormalities in the developing fetus. Chromosomal disorders such as Turner syndrome, Edwards syndrome, Patau syndrome, and down syndrome are some of the diseases which are screened using NIPT. The global non-invasive prenatal testing market is growing at a significant rate, due to mounting occurrence of chromosomal abnormalities, mounting maternal age and introduction of advanced products. Different products contributed to the non-invasive prenatal testing market size. The market has witnessed a high demand for consumables over the last few years due to repeated supplies of consumables as compared to instruments. The non-invasive prenatal testing (NIPT) market is a rapidly growing sector within the field of prenatal diagnostics. NIPT is a screening test that analyzes fetal DNA in the maternal blood to detect genetic abnormalities in the fetus. It offers a safer and more accurate alternative to traditional invasive procedures such as amniocentesis or chorionic villus sampling (CVS). The NIPT market has experienced significant growth in recent years due to several factors. First, advancements in technology, particularly in DNA sequencing and bioinformatics, have made it possible to detect fetal chromosomal abnormalities with high sensitivity and specificity. This has increased the reliability and accuracy of NIPT, making it a preferred choice for prenatal screening.
Insight by Product
On the basis of product, the market is subdivided into instruments and consumables. Repeated supplies of consumables are the factors responsible for the growth of the consumables segment. Of both the products, the consumables account the foremost share in the non-invasive prenatal testing market. The instruments market is further subdivided into next-generation sequencing systems, microarrays, ultrasound devices, polymerase chain reaction instruments, and others. In addition, consumables are further subdivided into disposables and assay kits & reagents
Insight by Method
On the basis of method, the market is subdivided into cell-free DNA in maternal plasma tests, ultrasound detection, fetal cell in maternal blood tests, and biochemical screening tests. Mounting need for cell free-DNA based techniques and expanding government schemes to offer prenatal services are the factors growing the demand for cell-free DNA in maternal plasma tests. Among all methods, the cell-free DNA in maternal plasma tests is expected to grow at the fastest rate in the non-invasive prenatal testing market. In addition, ultrasound detection segment accounted for the largest share in the market.
Insight by Application
On the basis of application, the market is subdivided into microdeletion syndrome, trisomy, and others. Increasing occurrence of chromosomal abnormalities with mounting maternal age is the factor responsible for the growth of the trisomy segment. Of all the applications, the trisomy accounted for the largest share and is expected to grow at the fastest rate in the non-invasive prenatal testing market.
Insight by End User
On the basis of end-user, the market is subdivided into hospitals and diagnostic laboratories. Mounting occurrence of chromosomal abnormalities and mounting schemes by companies to provide advanced products to diagnostic laboratories are some of the factors responsible for the growth of the diagnostic laboratories segment. Of both end-users, the diagnostic laboratories accounted for the largest share in the non-invasive prenatal testing market.
Global Non-Invasive Prenatal Testing Market Report Coverage
2018 - 2023
Base Year Considered
2025 - 2030
Market Size in 2023
U.S.D. 2.8 Billion
Revenue Forecast in 2030
U.S.D. 6.83 Billion
Segments Covered in the Report
By Product, By Method, By Application and By End User-User
Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Impact of COVID-19; Companies’ Strategic Developments; Market Share Analysis of Key Players; Company Profiling
Regions Covered in the Report
North America, Europe, Asia-Pacific, Middle East, and Rest of the World
The refining reimbursement scenario for NIPT, mounting occurrence of chromosomal abnormalities, Mounting average maternal age, and introduction of advanced products are the primary growth drivers for the non-invasive prenatal testing market. For instance, according to the World Health Organization (WHO), each year approximately 3,000 to 5,000 children are born with a chromosome disorder.
Budding inclination for non-invasive techniques, mounting healthcare expenditure and programs focusing on boosting the alertness of NIPT are also facilitating the growth for the non-invasive prenatal testing market.
The market for NIPT has been growing rapidly in recent years due to several factors. These include increasing maternal age, rising awareness and acceptance of genetic testing, advancements in technology, and the availability of a broader range of testing options. Additionally, the declining cost of genetic sequencing has made NIPT more accessible to a larger population.
The absence of skilled professionals and the consistency of test results in obese are the major challenges to the growth of non-invasive prenatal testing market. In addition, the ethical hurdle is also hindering the growth of the market. Social-cultural values and norms, misuse of NIPT for minor conditions, accessibility and affordability, justice, and fairness, permissibly legalizing termination of pregnancy due to a disability or any other undesired conditions, and others are some of the concerns associated with NIPT.
Globally, manufacturing companies trying to enter the non-invasive prenatal testing market are required to maintain stringent regulatory standards. Moreover, the high level of capital requirement also poses a major barrier to the entry of new players.
Increasing adoption: NIPT has gained widespread acceptance among pregnant women and healthcare professionals due to its high accuracy, low risk, and early detection capabilities.
Advancements in technology: The development of next-generation sequencing (NGS) and other advanced molecular techniques has greatly improved the accuracy and reliability of NIPT, leading to increased demand.
Rising maternal age: Advanced maternal age is associated with a higher risk of chromosomal abnormalities in fetuses. As women delay childbearing, there is a growing need for effective prenatal screening methods, further fueling the demand for NIPT.
Expanded applications: NIPT has expanded beyond detecting common chromosomal abnormalities to include screening for other genetic disorders and conditions, such as certain single-gene disorders and fetal aneuploidies.
Increasing awareness: Public awareness campaigns, educational initiatives, and improved accessibility to NIPT services have contributed to the market's growth by informing expectant parents about the benefits of non-invasive testing.
Geographically, North America is the largest non-invasive prenatal testing market as in the region the occurrence of chromosomal abnormalities is increasing. Mounting maternal age, improved healthcare infrastructure, and boosting alertness programs are also surging the growth of the North American non-invasive prenatal testing market. For instance, according to the Centre for Disease Control and Prevention (CDC) report on National Vital Statistics Report 2015, in the U.S., the mean age of a mother at first birth was 25.8 years in 2012, and it increased to 26 years in 2013.
Asia-Pacific is observed to witness the fastest growth in the market, due to mounting healthcare expenditure. In addition, boosting alertness programs and conferences is also creating a positive impact on the Non-invasive prenatal testing market growth in the region.
Key players in the non-invasive prenatal testing market are catering to the demand for these devices by investing in technologically advanced products in their product portfolio across the globe. In December 2017, PerkinElmer, Inc. acquired EUROIMMUN Medical Laboratory Diagnostics AG, to strengthen its position in China and other emerging countries. GE Healthcare, Perkinelmer, Inc., Koninklijke N.V., Qiagen, Pacific Biosciences of California, Inc., Agilent Technologies, Inc., and Beijing Genomics Institute are the key players offering non-invasive prenatal testing.
Pacific Biosciences of California, Inc., has acquired Omniome, to expand its market opportunities for sequencing innovative ways and add value to customers. Omniome has a novel approach to having an accurate short-read sequencing platform and entering large, fast-growing clinical applications such as oncology and non-invasive prenatal testing.
The Non-Invasive Prenatal Testing Market report offers a comprehensive market segmentation analysis along with an estimation for the forecast period 2025–2030.
Segments Covered in the Report
Region Covered in the Report
Source: VynZ Research